Research Paper Volume 14, Issue 23 pp 9715—9729
A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy
Figure 4. The Kaplan–Meier survival curve between the high-risk and low-risk groups of MIBC patients who received GC regimens. (A) Kaplan–Meier survival curve for the entire dataset; (B) Kaplan-Meier survival curve for AJCC pathology stage II; (C) Kaplan-Meier survival curve for AJCC pathology stage III; (D) Kaplan-Meier survival curve for AJCC pathology stage IV; (E) Kaplan-Meier survival curve for females; (F) Kaplan-Meier survival curve for males; (G) Kaplan-Meier survival curve for age ≥65; (H) Kaplan-Meier survival curve for age <65.